Cara Therapeutics (CARA) – Guidance
-
Cara Therapeutics (CARA) Prioritizes Late-Stage Notalgia Paresthetica Program, Extends Cash Runway into 2026
-
Cara Therapeutics (CARA) Reports Q4 Loss of $0.52/Share
-
-
-
-
-
-
Back to CARA Stock Lookup